
Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited treatment options, and poor prognosis—underscoring the importance of early diagnosis and specialized care and the need for therapies that can more effectively alter disease progression.